ArticleCell metabolism2015
Inflammasome inhibition: putting out the fire.
Article in Cell metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Atrial cardiomyopathy: From healthy atria to atrial failure. A clinical consensus statement of the Heart Failure Association of the ESC.European journal of heart failure · 2025Article
- Atherosclerosis: from lipid-lowering and anti-inflammatory therapies to targeting arterial retention of ApoB-containing lipoproteins.Frontiers in immunology · 2025Review
- NLRP3 Inflammasome Biomarker-Could Be the New Tool for Improved Cardiometabolic Syndrome Outcome.Metabolites · 2020Review
- NLRP3 Inflammasome and Its Critical Role in Gynecological Disorders and Obstetrical Complications.Frontiers in immunology · 2020Review
- Inflammasome activation and regulation: toward a better understanding of complex mechanisms.Cell discovery · 2020Review
- Chalcone Derivative L6H21 Reduces EtOH + LPS-Induced Liver Injury Through Inhibition of NLRP3 Inflammasome Activation.Alcoholism, clinical and experimental research · 2019Article
- Inflammation in the Pathophysiology and Therapy of Cardiometabolic Disease.Endocrine reviews · 2019Review
- Brucella abortus nitric oxide metabolite regulates inflammasome activation and IL-1β secretion in murine macrophages.European journal of immunology · 2019Article
- Inflammasomes: Pandora's box for sepsis.Journal of inflammation research · 2018Review
- HMGB1 Increases IL-1β Production in Vascular Smooth Muscle Cells via NLRP3 Inflammasome.Frontiers in physiology · 2018Article
- CD200Fc reduces LPS-induced IL-1β activation in human cervical cancer cells by modulating TLR4-NF-κB and NLRP3 inflammasome pathway.Oncotarget · 2017Article
- Inhibition of NLRP3 Inflammasome Pathway by Butyrate Improves Corneal Wound Healing in Corneal Alkali Burn.International journal of molecular sciences · 2017Article
- The Major Chromoblastomycosis Etiologic AgentFrontiers in immunology · 2017Article
- Article
- NLRP3 inflammasome and its inhibitors: a review.Frontiers in pharmacology · 2015Review
- Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease?Expert review of gastroenterology & hepatology · 2015Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NLRP3-inflammasome activates caspase-1 and processes pro-IL-1β and pro-IL-18 into the active cytokines. Two recent studies describe specific inhibitors of NLRP3 inflammasome that inhibit IL-1β release and inflammation. The specificity and potency of these compounds gives hope that a targeted approach to inhibit NLRP3-driven inflammation may be just around the corner.
Indexed as
Identifiers
25863243What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.